Literature DB >> 15177972

Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in Age-Related macular degeneration.

Sébastien Olivier1, David R Chow, Kirk H Packo, Mathew W MacCumber, Carl C Awh.   

Abstract

OBJECTIVE: To evaluate the anatomic and visual outcomes after a surgical procedure for displacement of thick submacular hemorrhage in patients with age-related macular degeneration.
DESIGN: Retrospective, noncomparative, interventional case series. PARTICIPANTS: Twenty-nine consecutive eyes of 28 patients with thick submacular hemorrhage secondary to age-related macular degeneration. INTERVENTION: The procedure consisted of a pars plana vitrectomy with subretinal recombinant tissue plasminogen activator injection (125 micrograms/ml) through a translocation microcannula, followed by fluid-air exchange and postoperative prone positioning [correction]. MAIN OUTCOME MEASURES: Intraoperative and postoperative surgical complications, preoperative and postoperative best-corrected visual acuities, postoperative fluorescein angiography results, and additional postoperative treatments.
RESULTS: Total subfoveal blood displacement was achieved in 25 eyes, with subtotal displacement in the others. Based on fluorescein angiography results, 8 eyes were eligible for additional postoperative treatments. At 3 months, 17 eyes had gained more than 2 lines of visual acuity, whereas 3 had lost more than 2 lines. The difference between preoperative and 3-month postoperative visual acuity was statistically significant (P = 0.0167). Complications consisted of 2 cases of vitreous hemorrhage that cleared within 4 weeks.
CONCLUSIONS: This surgical technique seems useful in displacing thick submacular hemorrhage secondary to age-related macular degeneration, allowing postoperative fluorescein angiography testing and, potentially, subsequent treatments. No significant complication from the procedure was identified. However, further controlled studies will be required to assess its efficacy in the management of this difficult clinical problem.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177972     DOI: 10.1016/j.ophtha.2003.10.020

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  43 in total

1.  [Subretinal co-application of rtPA and bevacizumab for exudative AMD with submacular hemorrhage. Compatibility and clinical long-term results].

Authors:  J Hillenkamp; A Klettner; S Puls; F Treumer; J Roider
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

2.  Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator.

Authors:  Jost Hillenkamp; Vladimir Surguch; Carsten Framme; Veit-Peter Gabel; Helmut G Sachs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-11       Impact factor: 3.117

3.  Management of macular hole and submacular hemorrhage in the same eye.

Authors:  Sophie J Bakri; Jonathan E Sears; Hilel Lewis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07-27       Impact factor: 3.117

4.  Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases.

Authors:  J J González-López; G McGowan; E Chapman; D Yorston
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

5.  [Subretinal hemorrhage. Natural course and staging].

Authors:  S Bopp
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

Review 6.  Clinical characteristics and current treatment of age-related macular degeneration.

Authors:  Yoshihiro Yonekawa; Ivana K Kim
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-03       Impact factor: 6.915

7.  Intrasurgical assessment of subretinal tPA injection for submacular hemorrhage in the PIONEER study utilizing intraoperative OCT.

Authors:  Justis P Ehlers; Daniel S Petkovsek; Alex Yuan; Rishi P Singh; Sunil K Srivastava
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-03       Impact factor: 1.300

8.  Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration.

Authors:  Luis Arias; Jordi Monés
Journal:  Clin Ophthalmol       Date:  2010-02-18

9.  Radiating hemorrhage in exudative age-related macular degeneration.

Authors:  Jae Hui Kim; Young Suk Chang; Jong Woo Kim; Tae Gon Lee; Chul Gu Kim; Dong Won Lee
Journal:  Jpn J Ophthalmol       Date:  2016-07-25       Impact factor: 2.447

10.  Treatment of massive subretinal hematoma associated with age-related macular degeneration using vitrectomy with intentional giant tear.

Authors:  Eisuke Isizaki; Seita Morishita; Takaki Sato; Masanori Fukumoto; Hiroyuki Suzuki; Teruyo Kida; Mari Ueki; Tsunehiko Ikeda
Journal:  Int Ophthalmol       Date:  2015-07-28       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.